Lyon, France, February 7, 2005
Flamel Technologies (NASDAQ:FLML) announced today
that it has posted a summary of Phase IIa data conducted
on Flamel's long-acting insulin, Basulin®, on
its website. (direct access to the document).
"We are pleased with the
results of the Phase IIa obtained on thirty (30) Type
I diabetic patients. This study confirms our strong
expectations for Basulin® because Medusa®,
our nano-particulate system, is the only one capable
to delivery human insulin with this level of efficacy,"
said Dr. Gerard Soula, founder, president and chief
executive officer of Flamel Technologies, S.A. "We
are actively looking for a partner capable of realizing
the full development and commercialization of Basulin®".
Flamel Technologies, S.A. is
a biopharmaceutical company principally engaged in
the development of two unique polymer-based delivery
technologies for medical applications. Micropump®
is a controlled release and taste- masking technology
for the oral administration of small molecule drugs.
Flamel's Medusa® technology is designed to deliver
controlled-release formulations of therapeutic proteins.
This document contains a number
of matters, particularly as related to financial projections
and the status of various research projects and technology
platforms, that constitute forward-looking statements
within the meaning of the Private Securities Litigation
Reform Act of 1995.
The presentation reflects the
current view of management with respect to future
events and is subject to risks and uncertainties that
could cause actual results to differ materially from
those contemplated in such forward-looking statements.
These risks include risks that
products in the development stage may not achieve
scientific objectives or milestones or meet stringent
regulatory requirements, uncertainties regarding market
acceptance of products in development, the impact
of competitive products and pricing, and the risks
associated with Flamel's reliance on outside parties
and key strategic alliances.
These and other risks are described
more fully in Flamel's Annual Report on the Securities
and Exchange Commission Form 20-F for the year ended
December 31, 2003.
CONTACT: Flamel Technologies,
Gerard Soula, (33) 4-72-78-34-34 Fax: (33) 4-72-78-34-35
or Stephen H. Willard, 202-862-3993 Fax: 202-862-3933
or Charles Marlio, 202-862-8535 Fax: 202-862-3933